Laser-welds sealed titanium battery housings for pacemakers and nerve stimulators that must run inside human bodies for up to ten years.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- Scale
Laser-welds sealed titanium battery housings for pacemakers and nerve stimulators that must run inside human bodies for up to ten years.
What this company is and how it runs — written from structure, not news.
Integer Holdings laser-welds titanium battery housings for implantable cardiac and neurostimulation devices — components that must run continuously inside a human body for up to a decade with no option to replace them if something goes wrong. The welding parameters that achieve a hermetic seal proven across that kind of lifecycle exist as process knowledge embedded in an FDA-approved manufacturing record, so a competitor buying the same equipment cannot replicate the outcome, and even Integer itself must restart an 18-to-24-month regulatory validation cycle before shipping any revised component to customers like Medtronic or Abbott. Because Medtronic and Abbott have physically tooled their production lines to Integer's specific connector shapes and battery dimensions, switching suppliers means retooling those lines and waiting through that same validation window — which means a customer cannot simply place a new order with someone else. The same laser-welding process that makes Integer hard to replace is also a single point of fragility: if a seal failure is traced to that process, the FDA can suspend the manufacturing authorization across every product line sharing those parameters at once, with no approved alternative sealing method available to fill the gap.
How does this company make money?
The company sells manufactured components — battery assemblies, leads, and pulse generator housings — directly to OEM customers like Medtronic and Abbott on a per-unit basis. Prices and volumes are set through annual supply agreements with purchase order commitments, so revenue tracks how many units the OEM customers order each period.
What makes this company hard to replace?
Switching to a different component supplier requires 12 to 18 months of biocompatibility testing and FDA validation before a single replacement part can legally ship — Medtronic or Abbott cannot simply place an order with someone new. Their manufacturing lines are also physically tooled to specific connector shapes and battery dimensions, so swapping suppliers means retooling the line, not just changing a purchase order. Devices already implanted in patients create ongoing service and accountability obligations that tie OEM customers to the original component supplier for years after a sale.
What limits this company?
Every new component shape or battery design requires 18 to 24 months of biocompatibility testing and FDA approval before it can ship — and that clock runs at the same speed no matter how much money is spent or how many workers are added. That fixed timeline is the ceiling on how fast the product range can grow or adapt to what OEM customers need.
What does this company depend on?
The company cannot operate without medical-grade lithium for the implantable battery cells, titanium and platinum alloys for the biocompatible housings, FDA 510(k) clearances for cardiovascular and neurostimulation components, ISO 13485 manufacturing certification, and cleanroom facilities that meet USP 797 standards. Lithium supply runs through mining operations in South America, adding a geographic dependency.
Who depends on this company?
Medtronic's pacemaker production lines would stop without the cardiac lead assemblies this company supplies. Abbott's neurostimulator manufacturing depends on its pulse generator components. Hospitals performing cardiac electrophysiology procedures would face delays without available implantable devices. Patients receiving spinal cord stimulation treatment depend on the neurostimulation battery systems it produces.
How does this company scale?
The battery cell production and hermetic sealing steps can be replicated across automated manufacturing lines using consistent materials, so volume can grow without a proportional increase in labor or cost. What cannot be sped up is the 18 to 24 month biocompatibility and FDA approval cycle that every new component design must complete before it can reach a customer — that bottleneck stays fixed no matter how large the operation grows.
What external forces can significantly affect this company?
When Medicare changes what it reimburses hospitals for cardiac device procedures, demand from OEM customers like Medtronic and Abbott rises or falls with it. The European Union's Medical Device Regulation is raising the amount of clinical evidence required to sell implantable components in Europe, which adds cost and time to market entry. Lithium supply from South American mining operations can tighten independently of anything the company does, threatening the material needed for every battery cell it produces.
Where is this company structurally vulnerable?
If a seal failure is traced back to the laser-welding process itself, the FDA can suspend that process across every product line that uses the same welding parameters at once. That would pull the manufacturing authorization that Medtronic and Abbott legally depend on to receive cleared components, trigger recalls for devices already implanted in patients, and leave no approved backup sealing method available to fill the gap.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Four observations co-occur: free cash flow positive each of the last three fiscal years, revenue increased each of the last three fiscal years, trailing-statistics OCF margin elevated, and book value increased each of the last four fiscal years. The configuration describes multi-year fundamental persistence across cash flow, top line, margin, and equity accumulation.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
Where is this company structurally exposed?
Two structural observations align: accounts receivable have increased year-over-year across the trailing four years, and receivables are a large share of current assets. Together they describe a receivables-heavy balance sheet whose receivables line keeps growing.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph